knowledge -WSS

knowledge

author：leisure time 2025-10-01 22:17:15 - browse：3734

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Can gargling with Listerine treat gonorrhea of the mouth?

WSS

Cybersecurity threat forces Lurie Children's to take systems offline

The real point of Kenneth Smith’s execution by nitrogen gas

Chemotherapy before breast cancer surgery might fuel metastasis

Empower primary care with adequate payments and technology

Welsh Carson private equity firm escapes from FTC antitrust case

Commercial surrogacy can be ethical, despite pope’s claims

leisure time

knowledge

focus

Medicare proposal to cover medical devices draws a mixed reaction

Vertex non

Trump demands the U.S. pay no more for drugs than other countries … again

Congressmen charge Covid hearing ‘could have been an email’

At least 13 dead in Texas as scorching temps continue

Most antidepressants don't work on kids, teens, study finds

Walensky prepares to leave CDC — and Congress — behind

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Sports medicine is finally prioritizing gender equality

Brain technologies pose threats that are all too real, experts warn

hotspot

Lawmakers grill UnitedHealth CEO on Change cyberattack

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Woodcock on FDA’s accelerated approval and her next chapter

FDA drug safety: Singulair case shows systemic surveillance flaws

Class action alleges UnitedHealth concealed DOJ probe

Medicare drug price negotiation’s day in court

hotspot

explore

Wikipedia

entertainment